90 related articles for article (PubMed ID: 26165033)
1. [Ways of handling surgical material from patients with colon cancer - standard and additional highly specialized research with colorectal cancer].
Nasierowska-Guttmejer A
Pol J Pathol; 2014 Dec; 65(4 Suppl 1):S40-50. PubMed ID: 26165033
[No Abstract] [Full Text] [Related]
2. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
Benedix F; Meyer F; Kube R; Kropf S; Kuester D; Lippert H; Roessner A; Krüger S
Pathol Res Pract; 2012 Oct; 208(10):592-7. PubMed ID: 22898351
[TBL] [Abstract][Full Text] [Related]
3. BRAF: a driver of the serrated pathway in colon cancer.
Rustgi AK
Cancer Cell; 2013 Jul; 24(1):1-2. PubMed ID: 23845435
[TBL] [Abstract][Full Text] [Related]
4. [Examination of molecular markers used n the treatment of colon cancer].
Domagała P; Kowalik A
Pol J Pathol; 2014 Dec; 65(4 Suppl 1):S59-77. PubMed ID: 26165036
[No Abstract] [Full Text] [Related]
5. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Tie J; Lipton L; Desai J; Gibbs P; Jorissen RN; Christie M; Drummond KJ; Thomson BN; Usatoff V; Evans PM; Pick AW; Knight S; Carne PW; Berry R; Polglase A; McMurrick P; Zhao Q; Busam D; Strausberg RL; Domingo E; Tomlinson IP; Midgley R; Kerr D; Sieber OM
Clin Cancer Res; 2011 Mar; 17(5):1122-30. PubMed ID: 21239505
[TBL] [Abstract][Full Text] [Related]
6. Molecular subtyping of colorectal cancer: time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome.
Fearon ER; Carethers JM
Gastroenterology; 2015 Jan; 148(1):10-3. PubMed ID: 25451650
[No Abstract] [Full Text] [Related]
7. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
[TBL] [Abstract][Full Text] [Related]
8. A correlation of the endoscopic characteristics of colonic laterally spreading tumours with genetic alterations.
Metz AJ; Bourke MJ; Moss A; Dower A; Zarzour P; Hawkins NJ; Ward RL; Hesson LB
Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):319-26. PubMed ID: 23354161
[TBL] [Abstract][Full Text] [Related]
9. NO147: the Giving Tree.
Leichman L
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24925351
[No Abstract] [Full Text] [Related]
10. Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer.
Nitsche U; Rosenberg R; Balmert A; Schuster T; Slotta-Huspenina J; Herrmann P; Bader FG; Friess H; Schlag PM; Stein U; Janssen KP
Ann Surg; 2012 Nov; 256(5):763-71; discussion 771. PubMed ID: 23095620
[TBL] [Abstract][Full Text] [Related]
11. Combining molecular markers with the TNM staging system to improve prognostication in stage II and III colon cancer: are we ready yet?
Sinicrope FA; Shi Q
J Natl Cancer Inst; 2012 Nov; 104(21):1616-8. PubMed ID: 23104213
[No Abstract] [Full Text] [Related]
12. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
Birgisson H; Edlund K; Wallin U; Påhlman L; Kultima HG; Mayrhofer M; Micke P; Isaksson A; Botling J; Glimelius B; Sundström M
BMC Cancer; 2015 Mar; 15():125. PubMed ID: 25884297
[TBL] [Abstract][Full Text] [Related]
14. [I. Molecular targeted therapy for unresectable wild type K-ras recurrent colon cancer].
Hikosaka T; Yamazaki K
Gan To Kagaku Ryoho; 2013 Nov; 40(11):1456-8. PubMed ID: 24319791
[No Abstract] [Full Text] [Related]
15. Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine.
Grothey A; Sargent DJ
JAMA Oncol; 2016 Sep; 2(9):1133-4. PubMed ID: 27273467
[No Abstract] [Full Text] [Related]
16. Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.
Netter J; Lehmann-Che J; Lambert J; Tallet A; Lourenco N; Soliman H; Bertheau P; Pariente B; Chirica M; Pocard M; Allez M; De The H; Gornet JM
Bull Cancer; 2015 Feb; 102(2):117-25. PubMed ID: 25609485
[TBL] [Abstract][Full Text] [Related]
17. [Pathologic diagnosis of colorectal cancer in the era of personalized therapy].
Lai M
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):73-6. PubMed ID: 24742564
[No Abstract] [Full Text] [Related]
18. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
[TBL] [Abstract][Full Text] [Related]
19. Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies.
Morikawa T; Tanaka N; Kuchiba A; Nosho K; Yamauchi M; Hornick JL; Swanson RS; Chan AT; Meyerhardt JA; Huttenhower C; Schrag D; Fuchs CS; Ogino S
Arch Surg; 2012 Aug; 147(8):715-23. PubMed ID: 22508672
[TBL] [Abstract][Full Text] [Related]
20. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
